Dyne Therapeutics (DYN) EBITDA (2019 - 2026)

Dyne Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$121.5 million for Q1 2026.

• In Q1 2026, EBITDA fell 5.51% year-over-year to -$121.5 million; the TTM figure through Mar 2026 stood at -$452.1 million (down 23.27% YoY), while the FY2025 annual figure was -$445.7 million, down 40.43% from the prior year.
• EBITDA was -$121.5 million for Q1 2026 at Dyne Therapeutics, down from -$112.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$36.2 million in Q1 2022 to a low of -$121.5 million in Q1 2026.
• Historically, EBITDA has averaged -$75.8 million across 5 years, with a median of -$65.8 million in 2024.
• Biggest YoY gain for EBITDA was 26.15% in 2022; the steepest drop was 75.52% in 2022.
• A 5-year view of EBITDA shows it stood at -$38.4 million in 2022, then slumped by 73.43% to -$66.6 million in 2023, then tumbled by 35.11% to -$90.0 million in 2024, then declined by 24.4% to -$112.0 million in 2025, then retreated by 8.48% to -$121.5 million in 2026.
• The last three EBITDA figures came in at -$121.5 million (Q1 2026), -$112.0 million (Q4 2025), and -$107.8 million (Q3 2025), per Business Quant data.